Loading patent…
AssigneePresident and Fellows of Harvard College
InventorsDavid A. Sinclair, Yuancheng Lu
Estimating the term…
Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).
1-57. (canceled)
A method of treating glaucoma in a subject in need thereof comprising administering to an eye of the subject a pharmaceutical composition comprising an expression vector comprising a polynucleotide encoding an octamer-binding transcription factor 4 (OCT4) protein, a sex determining region Y-box 2 (SOX2) protein, and a Kruppel-like factor 4 (KLF4) protein, wherein the polynucleotide does not encode a Myc proto-oncogene (c-Myc) protein, wherein the polynucleotide does not encode a Nanog protein, and wherein the polynucleotide is operably linked to at least one promoter.
A method of rejuvenating an optic nerve in a subject in need thereof comprising administering to an eye of the subject a pharmaceutical composition comprising an expression vector comprising a polynucleotide encoding an octamer-binding transcription factor 4 (OCT4) protein, a sex determining region Y-box 2 (SOX2) protein, and a Kruppel-like factor 4 (KLF4) protein, wherein the polynucleotide does not encode a Myc proto-oncogene (c-Myc) protein, wherein the polynucleotide does not encode a Nanog protein, and wherein the polynucleotide is operably linked to at least one promoter.
A method of treating damage to retinal ganglion cells in optic neuropathy in a subject in need thereof comprising administering to an eye of the subject a pharmaceutical composition comprising an expression vector comprising a polynucleotide encoding an octamer-binding transcription factor 4 (OCT4) protein, a sex determining region Y-box 2 (SOX2) protein, and a Kruppel-like factor 4 (KLF4) protein, wherein the polynucleotide does not encode a Myc proto-oncogene (c-Myc) protein, wherein the polynucleotide does not encode a Nanog protein, and wherein the polynucleotide is operably linked to at least one promoter.
A method of treating decline in retinal ganglion cell function in a subject suffering from age-related visual acuity loss comprising administering to an eye of the subject a pharmaceutical composition comprising an expression vector comprising a polynucleotide encoding an octamer-binding transcription factor 4 (OCT4) protein, a sex determining region Y-box 2 (SOX2) protein, and a Kruppel-like factor 4 (KLF4) protein, wherein the polynucleotide does not encode a Myc proto-oncogene (c-Myc) protein, wherein the polynucleotide does not encode a Nanog protein, and wherein the polynucleotide is operably linked to at least one promoter.
Dependencies are inferred from the claim text.